This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new PET radiotracer shows promise for diagnosing triple-negative breast cancer, researchers at Fudan University Shanghai Cancer Center in China have reported. In a bench-to-first-in-human study, the group found that the tracer was highly accurate at identifying tumors that express Nectin cell adhesion molecule 4 (nectin-4), an emerging biomarker for cancer diagnosis and therapy.
Medtech firm Subtle Medical has received clearance from the U.S. Food and Drug Administration (FDA) for its AI-powered Subtle-HD MRI acceleration and enhancement software. This clearance marks the launch of Subtles SubtleELITE suite of three AI-powered software tools: along with Subtle-HD, the suite includes SubtleSYNTH and SubtleALIGN, all collectively designed to work together to significantly both improve image quality and reduce MRI scan times, Subtle Medical said in a statement.
Researchers suggest the variables identified in their study should be considered when deciding whether to send patients for additional assessments to confirm or rule out malignancy.
Amidst rising cancer prevalence and soaring costs, new cancer technologies and innovations are emerging to support the early detection, treatment, and surveillance of cancer. Read this guide to understand how to evaluate these solutions for your employees and members – and to learn more about the current state of coverage, clinical and cost effectiveness, and impact on quality and outcomes.
Private radiology group Prenuvo raised $120 million in Series B funding in 2024. Co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis, the funding will accelerate Prenuvos augmentation of its core whole-body MRI screening with additional modalities and analyses of the human body, according to the company. The fundraising disclosure complements Prenuvo securing U.S.
tim.hodson Fri, 02/14/2025 - 15:14 Feb.12, 2025 Konica Minolta Healthcare Americas, has published a case study by clinicians in the pulmonary and radiology departments at ASST Fatebenefratelli Sacco (Milan, Italy) demonstrating the use of Dynamic Digital Radiography (DDR) to help definitively diagnose diaphragm dysfunction. The study, published in the journal Diagnostics, highlights the clinical value of DDR through its unique ability to evaluate diaphragm movement in real time and integrate dyn
tim.hodson Fri, 02/14/2025 - 15:14 Feb.12, 2025 Konica Minolta Healthcare Americas, has published a case study by clinicians in the pulmonary and radiology departments at ASST Fatebenefratelli Sacco (Milan, Italy) demonstrating the use of Dynamic Digital Radiography (DDR) to help definitively diagnose diaphragm dysfunction. The study, published in the journal Diagnostics, highlights the clinical value of DDR through its unique ability to evaluate diaphragm movement in real time and integrate dyn
Are low-field MRI units effective for neuroradiologic imaging? Perhaps, say researchers from the University of Michigan in Ann Arbor -- but more technological development is needed. Use of low-field MRI for this indication would improve patient care by expanding access to the modality, wrote a team led by medical student Lauren Kelsey. The group's commentary was published February 13 in RadioGraphics.
For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Representatives from the American College of Radiology (ACR) participated in the February American Medical Association (AMA) Current Procedure Terminology (CPT) Editorial Panel meeting, the first meeting of three scheduled for 2025 to update codes for the 2027 CPT code cycle. The ACR co-sponsored CPT code change proposals for Category I codes for prostate biopsy services and Category III codes for surface mesh volume.
Offering an array of AI-powered automation and image optimization, the new Elevate software is geared to maximizing workflow efficiencies for the EPIQ Elite and Affiniti ultrasound systems.
Patient-centric scheduling can only be achieved through optimized radiology workflows, effective communications between staff and physicians, and, of course, through specialized schedulers. In this guide, we’ll take you through a step-by-step process to transform your radiology center into a high-performance hub of medical imaging.
Contrast-enhanced conebeam breast CT (CBBCT) imaging features can help identify lymphovascular invasion (LVI) status in breast cancer patients, a study published February 13 in Academic Radiology found. A team led by ZhaoxiangYe, MD, PhD, from the National Clinical Research Center for Cancer in Tianjin, China, found that LVI was tied to various CT imaging features, including histologic type, Ki-67 index, and increased ipsilateral whole-breast vascularity (IIV) number and degree, among others.
Trust is low among U.S. adults when it comes to healthcare systems using AI responsibly and protecting patients from AI-related harms, show survey results published February 14 in JAMA Network Open. In their research, Paige Nong, PhD, from the University of Minnesota in Minneapolis, and Jodyn Platt, PhD, from the University of Michigan in Ann Arbor also found that general trust in the healthcare system is tied to low trust in medical AI.
About 40% of us will be diagnosed with cancer in our lifetime, and patients are getting younger. At the same time, the cost of treatment continues to rise, with employers spending 8.5% more on cancer care for each employee than they did last year. The best thing employers can do for their employees and business tomorrow is to invest in cancer detection and care today.
Discover how Color's comprehensive care solution is revolutionizing cancer screening adherence and knowledge. Through an in-depth case study, Color's unique approach to comprehensive cancer care has shown significant benefits in increasing screening rates and enhancing patient knowledge. Participants reported a 2-3x increase in adherence to screening guidelines over just 8 weeks, with 84% of participants increasing their familiarity with timing and frequency of cancer screening.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content